HC Wainwright & Co. Reiterates Buy on Satellos Bioscience, Maintains $18 Price Target
HC Wainwright & Co. analyst Arthur He reiterates Satellos Bioscience (NASDAQ:MSLE) with a Buy and maintains $18 price target.
Read original at benzingaStocks · News reference
Satellos Gets FDA Fast Track Status For Duchenne Drug
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jun 29, 2026, 11:15 AM
- Checked
- Jun 29, 2026, 11:20 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Satellos Bioscience Q2 EPS $(0.56) Misses $(0.45) Estimate
Satellos Bioscience (NASDAQ:MSLE) reported quarterly losses of $(0.56) per share which missed the analyst consensus estimate of $(0.45) by 24.44 percent. This is a 43.59 percent decrease over losses of $(0.39) per share
Read original at benzingaSatellos Bioscience Duchenne Drug Candidate's Interim Data Boosts Confidence
Satellos reports six-month interim data showing SAT-3247 improved muscle composition, maintained strength, and remained well-tolerated in DMD.
Read original at benzinga